

Schistosomiasis and hepatitis B co-infection

KAMALADIN AHMED SALIH

Faculty of Medicine and Health Science, University of Sennar

YAGOUB ABDALLA ABDERAHMAN

Sennar Teaching Hospital, Ultrasound Department

TAWADOD HAMZA ABUBAKER

ABDULRAHMAN ABDULLAHI ISHAG

Faculty of Medicine and Health Science, University of Sennar

Abstract:

Background: *Schistosomiasis is a significant health problem in Sudan and other countries in Africa, Asia and South America, with an infection rate of one in 30 individuals. Data on Schistosomiasis, Hepatitis B virus (HBV) co-infection are scarce; however, there is a high prevalence in countries where schistosomiasis is endemic. As elimination of schistosomiasis and (HBV) is a global target, there is a need for supplementary tools, such as vaccination, to confer long-term prevention.*

Methods: *A systematic search was performed in Sennar state (Sudan). The data was collected from 149 school student. In the period from 2013–2016, urine and blood analysis were done to test HBV and schist soma egg , master sheet containing these finding and personal data was performed, and analyzed by SPSS program.*

Results: *The study showed that 13% were suffering schist soma infection 25% of them co infected with hepatitis B. On the other hand 11% of all cases had hepatitis B infection 29% of them with schist soma infection, in respect the correlation between them it is significant.*

Conclusion: *It is clear this study is in line with universal studies in the field in that there were significant co infection between schist soma and hepatitis B, but there is controversy regarding the*

effects of HBV on schistosomiasis and vice versa. Vaccination might be a solution to the area of schistosomiasis.

Key words: Schistosomiasis, HBV, HCV, Hepatotropic, Vaccine, Adjuvant

INTRODUCTION

Schistosomiasis is a parasitic infection that is second to malaria in prevalence and affects about 200 million people in over 70 countries with an infection rate of one in 30 individuals [1,2].

Schistosomiasis is a complex tropical disease caused by *Schistosoma* species, of which *Schistosoma haematobium*, *S. mansoni*, and *S. japonicum* are the most common [3]. The diverse clinical patterns of this infection depend on the interplay of numerous factors, such as nutritional status, and co-infections [4-5]. Often, disease progresses to an advanced stage, called hepatosplenic schistosomiasis (HSS), which is frequently seen in endemic areas and is characterized by portal hypertension that may lead to gastrointestinal bleeding [6,7].

Concurrent infection between hepatitis B virus (HBV) and schistosomiasis is often observed in countries where schistosomiasis is endemic and might cause chronic liver inflammation [8]. *S. haematobium* and HBV co-infection pathogenesis remains cotraversal. This review was conducted to address the gap of knowledge regarding the above mentioned co-infections Epidemiology of co-infection with schistosomiasis, HBV in countries where schistosomiasis is endemic such as Egypt, a high prevalence of HBV and *S. mansoni* co-infection has been described ranging from 19.6 to 33.0% [9,10]. The prevalence of co-infection among the general population in Brazil is 15.8% [11]. In Yemen a group of researchers reported a relationship between *S. haematobium* and hepatitis B, but no correlation between *S. mansoni* infection and HBV or HCV [12]. It is understandable that hepato-splenic schistosomiasis renders

patients at risk of getting HCV owing to the involvement with the risk factors for both HBV and HCV such as history of treatment with parenteral treatment for schistosomiasis unsterile syringes during mass campaigns, blood transfusion, surgical and endoscopic interventions [10,13-14].

IMMUNOLOGY OF SCHISTOSOMIASIS AND HEPATITIS B OR C CO-INFECTION

Wahib et al., demonstrated the co-infection of HBV and/or HCV in 120 patients with hepatosplenic schistosomiasis was associated with a marked depression in cell mediated immune responses [15]. Furthermore, Edwards et al., described the effects of hepatotropic virus co infection during the Th2-dominated granulomatous phase of Schistosomal infection. They used lymphocytic choriomeningitis virus (LCMV) as a model for hepatotropic viruses, and demonstrated the induction of a strong LCMV-specific T cell response, with infiltration of large numbers of LCMV-specific interferon (IFN)- γ -producing CD8+ cells into the liver. This can lead to the down regulation of Th2 cytokine production that is dominant during *S. mansoni* infection and expeditious hepatotoxicity related morbidity. Moreover, livers of coinfecting mice were highly susceptible to viral replication, which correlated with a reduction in intrahepatic type I IFN responses following virus infection [15-16].

Impact of co-infection with schistosomiasis and HBV on the individual disease course Chronic infections with hepatotropic viruses, such as HBV, can lead to liver cirrhosis, and an expected synergistic effect might exacerbate hepatic pathology during concomitant infections of HBV and schistosomiasis. Epidemiological studies were performed to investigate schistosomiasis/HBV co-infections, as no suitable animal models exist. A number of studies proposed an increased susceptibility to HBV caused by schistosomal

infections (especially the severe hepatosplenic form)[17,18]. However, this could be explained by the frequent need of schistosomiasis patients for blood transfusion, especially on considering the poor infection control measures in countries where this disease is endemic. In contrast, other studies rejected the thesis stating any relationship between schistosomiasis and HBV [19,20].

Woodchucks are susceptible to infection with both schistosoma and woodchuck hepatitis virus (WHV) [21]. Because HBV and WHV descend from the same family (family Hepadnaviridae), a concomitant infection of schistosomes and WHV in woodchucks might be a suitable animal model for concomitant infection in humans. However, there was no impact of schist soma infection on WHV serum markers [22]. HBV replication was inhibited in transgenic mice [23] during schistosomal infection, where the antiviral effects of schistosomes related to IFN- γ and nitric oxide. Thus, most published studies have found no association between schistosomiasis and worsening of HBV infection [24]. In contrast, other studies described a poor prognosis of HBV when associated with hepatosplenic schistosomiasis [28,29,25]. Interestingly HBV vaccines (both 1st and 2nd generation) can mount an immune response in schistosomiasis patients; however, reduced responses to vaccination were seen in hepatosplenic schistosomiasis [30,26,27].

Therefore, further studies are needed to determine conclusions regarding co-infection schistosomiasis and HBV.

THE PROBLEM

Sennar is an agricultural state, rich in canals and lakes, because of that most of the population have schistsoma infection during their life's, This study tried to touch concomitant infections of HBV and schistosomiasis, their expected synergistic Effect that might exacerbate hepatic

pathology and the need for supplementary tools, such as vaccination, to confer long-term prevention.

METHODS:

A systematic search was performed in Sennar state (Sudan). The data was collected from 149 healthy school student all were children i.e less than 12years old. In the period from 2013–2016, urine and blood analysis were done to test HBV and schist soma egg , master sheet containing these finding and personal data was performed, and analyzed by SPSS program

Objective

The main objective of this research is to study concomitant infections of HBV and schistosomiasis.

RESULTS

Table (1) sex

Cumulative Percent	Valid Percent	Percent	Frequency	
48.3	48.3	48.3	72	male Valid
100.0	51.7	51.7	77	female
	100.0	100.0	149	Total

Table 2 age

Cumulative Percent	Valid Percent	Percent	Frequency	
22.1	22.1	22.1	33	less than 10 Valid
78.5	56.4	56.4	84	10-12
100.0	21.5	21.5	32	more than 12
	100.0	100.0	149	Total

Table 3 schist soma

Cumulative Percent	Valid Percent	Percent	Frequency	
13.4	13.4	13.4	20	yes Valid
100.0	86.6	86.6	129	no infection
	100.0	100.0	149	Total

Table (4) hepatitis B

Cumulative Percent	Valid Percent	Percent	Frequency	
88.6	88.6	88.6	132	no infection
100.0	100.0	100.0	149	yes
				Total

Table (5) SCHISTO * HB Crosstabulation

Count

Total	HB		
	yes	no infection	
20	5	15	yes
129	12	117	no infection
149	17	132	Total

Figure (1) SCHISTO * HB Crosstabulation




Table (6) SEX * HB Correlations

SEX	HB		
-.075	1	Pearson	HB
.361	.	Correlation	
149	149	Sig. (2-tailed)	
		N	
1	-.075	Pearson	SEX
.	.361	Correlation	
149	149	Sig. (2-tailed)	
		N	

Table (7) AGE * HBCorrelations

AGE	HB		
.068	1	Pearson	HB
.413	.	Correlation	
149	149	Sig. (2-tailed)	
		N	
1	.068	Pearson	AGE
.	.413	Correlation	
149	149	Sig. (2-tailed)	
		N	

Table (5) SCHISTO * HB Correlations

HB	SCHISTO		
-.168(*)	1	Pearson Correlation	SCHISTO
.040	.	Sig. (2-tailed)	
149	149	N	
1	-.168(*)	Pearson Correlation	HB
.	.040	Sig. (2-tailed)	
149	149	N	

* Correlation is significant at the 0.05 level (2-tailed).

DISCUSSION

The total number of school children selected for this study was 149cases of both genders (52% were female, and 48% were male table 1), 22% of them their age less than 10years old, 57% from 10 to 12years old and 21% more than 12 years old (table 2). The study showed that 13% were suffering schist soma infection 25% of them co infected with hepatitis B (table 3, table 5, and figure 1). On the other hand had 11% of all cases had hepatitis B infection 29% of them with schist soma infection (table 4, table 5 and figure 1).

In respect to correlation test between the hepatitis B virus infection and gender no significant relationship between them(table 6), it is same for hepatitis and age (table 7), but it is significant positively in correlation between hepatitis B infection and schist soma infection with Sig. (2-tailed) is 0.04 (table 8), this in line with Du H he found that high (58.4%) prevalence of HBV was among Chinese patients with chronic schistosomiasis (31) and Al-Shamiri who mentioned a strong

relationship between schistosoma hematopium and HBV co-infection in Yemen population(12).

RECOMMENDATION

1/ mass treatment for all people in high endemic area of schistosoma especially those living near damp lakes, canals and annual autumn lakes.

2/HBV vaccination to same groups of high endemic area of schistomiasis as a high risk patient

3/ routine screening and investigations for HBV infection amongst schistosoma infection patients.

4/more research and studies to detect the exact route of co-transmission of schistosoma and HBV infection in low risk individuals (least sexual activity, and minimum blood transfusion children)

CONCLUSION

This study was conducted in Sennar state (Sudan), on 149 school student, in the period from 2013 -2016. The goal of this research is to study concomitant infections of HBV and schistosoma hematopium.

The study showed that 13% were suffering schistosoma infection 25% of them co infected with hepatitis B. On the other hand 11% of all cases had hepatitis B infection 29% of them with schist soma infection, in respect the correlation between them it is significant. This study recommended that mass treatment for all people in high endemic area of schistosoma infected patients and HBV vaccination to them.

REFERENCES

1. WHO: Status of Schistosomiasis endemic countries. Geneva: World Health Organization; 2012. apps.who.int/neglected_diseases/ntddata/sch/sch.html.
2. Schistosomiasis Control Program: The Carter Center <http://www.cartercenter.org/resources/pdfs/factsheets/schistosomiasis-facts.pdf>. Accessed 2011 Nov 15
3. Schmitt, I: Schistosomiasis—The burden of disease and trends of intervention. *International Health Practice*; April 2006. <http://www.case.edu/med/epidbio/mphp439/Schistosomiasis.ht>.
4. Blanton RE, Salam EA, Kariuki HC, Magak P, Silva LK, Muchiri EM, et al. Population-based differences in Schistosomiasis mansoni and hepatitis C induced disease. *J Infect Dis.* 1859; 2002:1644–A
5. Mohamed-Ali Q, Elwali NE, Abdelhameed AA, Mergani A, Rahoud S, Elagib KE, et al. Susceptibility to periportal (Symmers) fibrosis in human Schistosomamansoni infections: evidence that intensity and duration of infection, gender and inherited factors are critical in disease progression. *J Infect Dis.* 1999;180: 1298–306.
6. Elbaz T, Esmat G. Hepatic and Intestinal Schistosomiasis: Review. *JAR.* 2013;4:445–52.
7. Pereira LM, Domingues AL, Spinelli V, McFarlane IG. Ultrasonography of the liver and spleen in Brazilian patients with hepatosplenic Schistosomiasis and cirrhosis. *Trans R Soc Trop Med Hyg.* 1998;92:639–42.
8. Conceicao MJ, Argento CA, Chagas VL, Takiya CM, Moura DC, Silva SC. Prognosis of Schistosomiasis mansoni patients infected with hepatitis B virus. *Mem Inst Oswaldo Cruz.* 1998;93:255–8
9. El-Sayed HF, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to

a newly reclaimed area endemic for *Schistosoma mansoni* in Sinai, Egypt. *Acta Trop.* 1997;68:229–37.

10. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. *J Hepatol.* 1997;26:236–43.

11. Aquino RT, Chieffi PP, Catunda SM, Araújo MF, Ribeiro MC, Taddeo EF, et al. Hepatitis B and C virus markers among patients with hepatosplenic mansonic schistosomiasis. *Rev Inst Med Trop Sao Paulo.* 2000;42:313–20.

12. AH, Al-Taj MA, Ahmed AS. Prevalence and co-infections of schistosomiasis/hepatitis B and C viruses among school children in an endemic area in Taiz, Yemen. *Asian Pac J Trop Med.* 2011;4:404–8.

13. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. *Hepatology.* 2001;33:248–53

14. Edris A, Nour MO, Zedan OO, Mansour AE, Ghandour AA, Omran T. Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate. *Egypt East Mediterr Health J.* 2014;20:605–13.

15. Wahib AA, Masoud AA, Halem AA, Haseeb AN, Hassan AR, Darwish MA, et al. Cell mediated immune response in chronic liver diseases: schistosomal, viral and neoplastic. *J Egypt Soc Parasitol.* 1998;28:929–39.

16. Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, et al. Chronic *Schistosoma japonicum* infection reduces immune response to vaccine against hepatitis B in mice. *PLoS One.* 2012;7:e 51512

17. Hammad HA, el Fattah MM, Moris M, Madina EH, el Abbasy AA, Soliman AT. Study on some hepatic functions and prevalence of hepatitis B surface antigenaemia in Egyptian children with Schistosomal hepatic fibrosis. *J Trop Pediatr.* 1990;36:126–7.

18. Al-Freihi HM. Prevalence of hepatitis B surface antigenemia among patients with *Schistosoma mansoni*. *Ann Saudi Med*. 1993;13:121–5.
19. Larouze B, Dazza MC, Gaudebout C, Habib M, Elamy M, Cline B. Absence of relationship between *Schistosoma mansoni* and hepatitis B virus infection in the Qalyub Governate, Egypt. *Ann Trop Med Parasitol*. 1987;81:373–5.
20. Ye XP, Fu YL, Anderson RM, Nokes DJ. Absence of relationship between *Schistosoma japonicum* and hepatitis B virus infection in the Dongting lake region, China. *Epidemiology and Infection*. 1998;121:193–5.
21. Andrade ZA, Berthillon P, Paran  R, Grimaud JA, Tr po C. Schistosomiasis mansoni and viral B hepatitis in woodchucks. *J Hepatol*. 2001;34:134–9.
22. Osada Y, Kanazawa T. Schistosome: its benefit and harm in patients suffering from concomitant diseases. *J Biomed Biotechnol*. 2011;2011:264173.
23. McClary H, Koch R, Chisari FV, Guidotti LG. Inhibition of hepatitis B virus replication during *Schistosoma mansoni* infection in transgenic mice. *J Exp Med*. 2000;192:289–94.
24. Maria Jos  Concei o and Jos  Rodrigues Coura (2013): Study on Schistosomiasis mansoni and Comorbidity with Hepatitis B and C Virus Infection, *Parasitic Diseases - Schistosomiasis*, Prof. Rashika El Ridi (Ed.), ISBN:978-953-51-0942-6, InTech. Available from: <http://www.intechopen.com/books/parasitic-diseases-Schistosomiasis/study-on-Schistosomiasis-mansoni-and-comorbidity-with-hepatitis-b-and-c-virus-infection>
25. Andrade JR, Silva LD, Guimar es CM, Bassetti-Soares E, Cambraia RD, Couto OF, et al. Chronic hepatitis B and liver schistosomiasis: a deleterious association. *Trans R Soc Trop Med Hyg*. 2014;108:159–64.
26. Lundy SK, Lukacs NW. Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression. *Front Immunol*. 2013;4:39.

27. Bassily S, Strickland GT, Abdel-ahab MF, Esmat GE, Narooz S, el-Masry NA, et al. "Efficacy of hepatitis B vaccination in primary school children from avillage endemic for *Schistosoma mansoni*,". *J Infect Dis.* 1992;166:265–8.
28. Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed KK, Peter T, et al. Acute hepatitis C without and with Schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. *Gastroenterology.* 2001;121:646–56.
29. Van-Lume DS, Albuquerque Mde F, Souza AI, Domingues AL, Lopes EP, Morais CN, et al. Association between Schistosomiasis mansoni and hepatitis C: systematic review. *Rev Saude Publica.* 2013;47:414–24.
30. Edwards MJ, Buchatska O, Ashton M, Montoya M, Bickle QD, Borrow P. Reciprocal immunomodulation in a schistosome and hepatotropic virus coinfection model. *J Immunol.* 2005;175:6275–85.
31. Du H. Relationship between advanced schistosomiasis and HBV infection. *Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi.* 2013; 25:115–7.